# PANFIRE-3 Trial: Assessing Safety and Efficacy of Irreversible Electroporation (IRE) + Nivolumab + CpG for Metastatic Pancreatic Cancer

> **NCT04612530** · PHASE1 · UNKNOWN · sponsor: **Amsterdam UMC, location VUmc** · enrollment: 18 (estimated)

## Conditions studied

- Pancreatic Cancer
- Metastatic Pancreatic Cancer

## Interventions

- **DEVICE:** Irreversible Electroporation (IRE)
- **DRUG:** Nivolumab
- **DRUG:** Toll-Like Receptor 9

## Key facts

- **NCT ID:** NCT04612530
- **Lead sponsor:** Amsterdam UMC, location VUmc
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-09-01
- **Primary completion:** 2023-04-01
- **Final completion:** 2023-06-01
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2022-12-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04612530

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04612530, "PANFIRE-3 Trial: Assessing Safety and Efficacy of Irreversible Electroporation (IRE) + Nivolumab + CpG for Metastatic Pancreatic Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04612530. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*